摘要 |
Described are compounds of Formula I, which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-IR), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c- FMS, c-KIT, or PDGFR kinases. |
申请人 |
DECIPHERA PHARMACEUTICALS, LLC;CALDWELL, TIMOTHY MALCOLM;PATT, WILLIAM C.;SAMARAKOON, THIWANKA;VOGETI, LAKSHMINARAYANA;YATES, KAREN M. |
发明人 |
CALDWELL, TIMOTHY MALCOLM;PATT, WILLIAM C.;SAMARAKOON, THIWANKA;VOGETI, LAKSHMINARAYANA;YATES, KAREN M.;FLYNN, DANIEL L.;KAUFMAN, MICHAEL D. |